Document Detail


Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
MedLine Citation:
PMID:  11520150     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The present study was planned to measure preoperative levels of soluble urokinase plasminogen activator receptor (suPAR) in plasma from patients with gynecological diseases, and to test for a relationship to clinical and biochemical patient characteristics. METHODS: Using a specific and sensitive kinetic ELISA, suPAR levels were determined in preoperative citrate plasma samples from 53 ovarian, 34 endometrial, and 30 cervical cancer patients, 17 patients with benign ovarian tumors, and 28 patients with benign endometrial diseases. In addition, suPAR was measured in citrate samples from 31 female blood donors. RESULTS: suPAR was measurable in all samples. No significant difference was found between plasma suPAR in the blood donors and the patients with benign diseases (P = 0.58). The groups of cancer patients had suPAR levels that were significantly higher than those found in the blood donors (P < 0.0001, P < 0.0001, and P = 0.001 for patients with ovarian, endometrial, and cervical cancer, respectively). In all groups of cancer patients a trend toward increasing suPAR levels with increasing FIGO stage was noted (P = 0.0003, P = 0.02, and P = 0.01 for patients with ovarian, endometrial, and cervical cancer, respectively). Using the median suPAR level to dichotomize the ovarian cancer patients, FIGO stages I-III, a significantly increased risk of progression/relapse was found for patients with high suPAR levels (Hazard ratio (HR) = 3.1, 95% CI: 1.1-8.8, P = 0.03). A multivariate analysis was performed, including suPAR, FIGO stage, and CA-125. Only FIGO stage III compared with FIGO stage I was significant (HR = 15, 95% CI: 1.8-129, P = 0.01). Survival analyses were not performed in the endometrial or cervical cancer patients due to few progressions/relapses during the follow-up period. CONCLUSION: This study concludes that patients with gynecological cancers have elevated plasma suPAR levels as compared with healthy female blood donors and patients with benign gynecological diseases. In addition, high preoperative plasma levels of suPAR are significantly associated with poor outcome of ovarian cancer patients. However, additional studies are needed to further validate the clinical usefulness of plasma suPAR measurements in the management of ovarian cancer patients.
Authors:
R Riisbro; R W Stephens; N Brünner; I J Christensen; H J Nielsen; L Heilmann; G F von Tempelhoff
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Gynecologic oncology     Volume:  82     ISSN:  0090-8258     ISO Abbreviation:  Gynecol. Oncol.     Publication Date:  2001 Sep 
Date Detail:
Created Date:  2001-08-24     Completed Date:  2001-09-20     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0365304     Medline TA:  Gynecol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  523-31     Citation Subset:  IM    
Copyright Information:
Copyright 2001 Academic Press.
Affiliation:
Finsen Laboratory, Rigshospitalet, DK-2100 Copenhagen, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
CA-125 Antigen / blood
Disease-Free Survival
Endometrial Neoplasms / blood*,  immunology,  pathology
Enzyme-Linked Immunosorbent Assay
Female
Humans
Middle Aged
Multivariate Analysis
Neoplasm Staging
Ovarian Diseases / blood,  pathology
Ovarian Neoplasms / blood*,  immunology,  pathology
Preoperative Care
Receptors, Cell Surface / blood*
Receptors, Urokinase Plasminogen Activator
Sensitivity and Specificity
Solubility
Uterine Cervical Neoplasms / blood*,  immunology,  pathology
Uterine Hemorrhage / blood,  pathology
Chemical
Reg. No./Substance:
0/CA-125 Antigen; 0/PLAUR protein, human; 0/Receptors, Cell Surface; 0/Receptors, Urokinase Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Biopsy correlates of abnormal cervical cytology classified using the Bethesda system.
Next Document:  Identification of prognostic factors in advanced epithelial ovarian carcinoma.